Investors
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.
With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include potentially differentiated product candidates against validated targets.
Press Releases
July 11, 2022
June 17, 2022
June 2, 2022
FRONT >> News > View All
Latest Events
June 10, 2022 at 10:30 AM EDT
February 16, 2022 at 4:20 PM EST
January 5, 2022 at 8:30 AM EST
FRONT > Events - View All
Stock Quote
- Change
- Volume
- Today's Open
- Previous Close
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FRONT >> Stock > View All
Email Alerts
Investor Contact
Ina McGuinness
Tel: +1 (212) 867-1768
imcguinness@connectpharm.com